DNA repair and gene therapy: Implications for translational uses

Melissa Limp-Foster, Mark Kelley

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Gene therapy has been proposed to have implications in the treatment of cancer. By genetically manipulating the hematopoietic stem cell compartment with genes that confer resistance to chemotherapeutic agents, the dose escalation that is necessary to effectively treat the cancers could potentially be achieved. DNA repair genes are some of the potential candidates to confer increased resistance to chemotherapeutic agents. Although initial focus in this area has been on the direct reversal protein (MGMT), its protective ability is limited to those agents that produce O6- methylGuanine cross-links-agents that are not extensively used clinically (e.g., nitrosoureas). Furthermore, most alkylating agents attack more sites in DNA other than O6-methylGuanine, such that the protections afforded by MGMT may prevent the initial cytotoxicity, but at a price of increased mutational burden and potential secondary leukemias. Therefore, some of the genes that are being tested as candidates for gene transfer are base excision repair (BER) genes. We and others have found that overexpression of selective BER genes confers resistance to chemotherapeutic agents such as thiotepa, ionizing radiation, bleomycin, and other agents. As these 'proof of concept' analyses mature, many more clinically relevant chemotherapeutic agents can be tested for BER protective ability. (C) 2000 Wiley-Liss, Inc.

Original languageEnglish
Pages (from-to)71-81
Number of pages11
JournalEnvironmental and Molecular Mutagenesis
Volume35
Issue number2
DOIs
StatePublished - 2000

Fingerprint

Gene therapy
DNA Repair
Genetic Therapy
repair
Repair
DNA
gene
Genes
cancer
Thiotepa
Gene transfer
gene transfer
Alkylating Agents
Bleomycin
Hematopoietic Stem Cells
Ionizing Radiation
Ionizing radiation
Cytotoxicity
therapy
Stem cells

Keywords

  • Cancer
  • DNA repair
  • Gene therapy
  • Hematopoiesis

ASJC Scopus subject areas

  • Environmental Science(all)
  • Environmental Chemistry
  • Genetics
  • Genetics(clinical)
  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

DNA repair and gene therapy : Implications for translational uses. / Limp-Foster, Melissa; Kelley, Mark.

In: Environmental and Molecular Mutagenesis, Vol. 35, No. 2, 2000, p. 71-81.

Research output: Contribution to journalArticle

@article{f825a2628db748bcbebb25531c1a84f7,
title = "DNA repair and gene therapy: Implications for translational uses",
abstract = "Gene therapy has been proposed to have implications in the treatment of cancer. By genetically manipulating the hematopoietic stem cell compartment with genes that confer resistance to chemotherapeutic agents, the dose escalation that is necessary to effectively treat the cancers could potentially be achieved. DNA repair genes are some of the potential candidates to confer increased resistance to chemotherapeutic agents. Although initial focus in this area has been on the direct reversal protein (MGMT), its protective ability is limited to those agents that produce O6- methylGuanine cross-links-agents that are not extensively used clinically (e.g., nitrosoureas). Furthermore, most alkylating agents attack more sites in DNA other than O6-methylGuanine, such that the protections afforded by MGMT may prevent the initial cytotoxicity, but at a price of increased mutational burden and potential secondary leukemias. Therefore, some of the genes that are being tested as candidates for gene transfer are base excision repair (BER) genes. We and others have found that overexpression of selective BER genes confers resistance to chemotherapeutic agents such as thiotepa, ionizing radiation, bleomycin, and other agents. As these 'proof of concept' analyses mature, many more clinically relevant chemotherapeutic agents can be tested for BER protective ability. (C) 2000 Wiley-Liss, Inc.",
keywords = "Cancer, DNA repair, Gene therapy, Hematopoiesis",
author = "Melissa Limp-Foster and Mark Kelley",
year = "2000",
doi = "10.1002/(SICI)1098-2280(2000)35:2<71::AID-EM1>3.0.CO;2-P",
language = "English",
volume = "35",
pages = "71--81",
journal = "Environmental and Molecular Mutagenesis",
issn = "0893-6692",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - DNA repair and gene therapy

T2 - Implications for translational uses

AU - Limp-Foster, Melissa

AU - Kelley, Mark

PY - 2000

Y1 - 2000

N2 - Gene therapy has been proposed to have implications in the treatment of cancer. By genetically manipulating the hematopoietic stem cell compartment with genes that confer resistance to chemotherapeutic agents, the dose escalation that is necessary to effectively treat the cancers could potentially be achieved. DNA repair genes are some of the potential candidates to confer increased resistance to chemotherapeutic agents. Although initial focus in this area has been on the direct reversal protein (MGMT), its protective ability is limited to those agents that produce O6- methylGuanine cross-links-agents that are not extensively used clinically (e.g., nitrosoureas). Furthermore, most alkylating agents attack more sites in DNA other than O6-methylGuanine, such that the protections afforded by MGMT may prevent the initial cytotoxicity, but at a price of increased mutational burden and potential secondary leukemias. Therefore, some of the genes that are being tested as candidates for gene transfer are base excision repair (BER) genes. We and others have found that overexpression of selective BER genes confers resistance to chemotherapeutic agents such as thiotepa, ionizing radiation, bleomycin, and other agents. As these 'proof of concept' analyses mature, many more clinically relevant chemotherapeutic agents can be tested for BER protective ability. (C) 2000 Wiley-Liss, Inc.

AB - Gene therapy has been proposed to have implications in the treatment of cancer. By genetically manipulating the hematopoietic stem cell compartment with genes that confer resistance to chemotherapeutic agents, the dose escalation that is necessary to effectively treat the cancers could potentially be achieved. DNA repair genes are some of the potential candidates to confer increased resistance to chemotherapeutic agents. Although initial focus in this area has been on the direct reversal protein (MGMT), its protective ability is limited to those agents that produce O6- methylGuanine cross-links-agents that are not extensively used clinically (e.g., nitrosoureas). Furthermore, most alkylating agents attack more sites in DNA other than O6-methylGuanine, such that the protections afforded by MGMT may prevent the initial cytotoxicity, but at a price of increased mutational burden and potential secondary leukemias. Therefore, some of the genes that are being tested as candidates for gene transfer are base excision repair (BER) genes. We and others have found that overexpression of selective BER genes confers resistance to chemotherapeutic agents such as thiotepa, ionizing radiation, bleomycin, and other agents. As these 'proof of concept' analyses mature, many more clinically relevant chemotherapeutic agents can be tested for BER protective ability. (C) 2000 Wiley-Liss, Inc.

KW - Cancer

KW - DNA repair

KW - Gene therapy

KW - Hematopoiesis

UR - http://www.scopus.com/inward/record.url?scp=0034121347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034121347&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1098-2280(2000)35:2<71::AID-EM1>3.0.CO;2-P

DO - 10.1002/(SICI)1098-2280(2000)35:2<71::AID-EM1>3.0.CO;2-P

M3 - Article

C2 - 10712740

AN - SCOPUS:0034121347

VL - 35

SP - 71

EP - 81

JO - Environmental and Molecular Mutagenesis

JF - Environmental and Molecular Mutagenesis

SN - 0893-6692

IS - 2

ER -